Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018


Posted on: 01 Mar 18


ORION CORPORATION         STOCK EXCHANGE RELEASE         1 MARCH 2018   at 19.10 EET            


Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018


In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2018  transferred altogether 112,961 Orion Corporation B shares held by the company as a share reward for earning periods 2015-2017 and 2017 to the persons belonging to the Share-based Incentive Plans of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 22 March 2016.

The price per share of the transferred shares is EUR 26.5238, which is the volume weighted average quotation of the Orion Corporation B share on 1 March 2018. Accordingly, the total transaction price of the transferred shares is EUR 2,996,154.97.

After the share transfer, the total number of own B shares held by Orion Corporation is 562,440.

Orion Corporation has informed about the Share-based Incentive Plans in stock exchange releases on 5 February 2013 and on 2 February 2016.

 
Orion Corporation

 

Timo Lappalainen
President and CEO
  Olli Huotari
SVP, Corporate Functions
 


                                                                                                                                  
Contact person:
Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054, mobile +358 50 966 3054
 
 
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
 
 
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,085 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki.

GlobeNewswire
globenewswire.com

Last updated on: 02/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.